Rebamipide in gastric mucosal protection and healing: An Asian perspective

doi:10.4292/wjgpt.v16.i1.101753

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=0

Mar 5, 2025 (publication date) through Mar 3, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Pharmacol Ther. Mar 5, 2025; 16(1): 101753
Published online Mar 5, 2025. doi: 10.4292/wjgpt.v16.i1.101753

Rebamipide in gastric mucosal protection and healing: An Asian perspective

Manish Kak

Manish Kak, Department of Gastroenterology, Manipal Hospital, Ghaziabad 201002, Uttar Pradesh, India

Author contributions: Kak M contributed to conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualization and writing review and editing; the author has approved the final version of the article to be published.

Supported by Dr Reddy's Laboratories, Hyderabad, India.

Conflict-of-interest statement: The author declares no conflict of interest in publishing the manuscript.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Manish Kak, DNB, FACG, MBBS, MD, MNAMS, Doctor, Department of Gastroenterology, Manipal Hospital, NH-24 Hapur Road, Near Landcraft Golflinks, Pandav Nagar, Ghaziabad 201002, Uttar Pradesh, India. manishkak@yahoo.com

Received: September 26, 2024
Revised: December 5, 2024
Accepted: January 2, 2025
Published online: March 5, 2025
Processing time: 158 Days and 0.1 Hours

Core Tip

Core Tip: This review highlights rebamipide’s superior safety and efficacy in treating gastric ulcers and mucosal disorders, making it a strong candidate for inclusion in global treatment guidelines. An extensive literature review reveals its multifaceted mechanism of action, including prostaglandin synthesis, free radical scavenging, and mucin production enhancement, leading to enhanced mucosal protection and ulcer healing. Rebamipide often surpasses other common treatments like pantoprazole and esomeprazole due to its low adverse event rate and mild side effects. Its broad application extends to ophthalmology, oncology, and bone regeneration, further underscoring its therapeutic versatility.